CYP2D6 and chronic myelogenous leukemia, BCR-ABL1 positive: The importance of identifying CYP2D6 as a potential CML risk factor may aid in better predicting the outcome of treatment; as the availability of predictive biomarkers for drug response can become indispensable guidance for the proper initiation and surveillance of dosage and treatment efficacy.